We believe Prestige is in fine financial health. At the end of fiscal 2024, the company had roughly $46 million in cash and equivalents with about $1.1 billion in long-term debt. Majority of debt was ...

In Consumer Healthcare, we continue to increase capacity for our previously highlighted patented lateral control system technology with a one push button ... ease of use for Haleon's Otrivin ...

And Gentrack is really well placed to continue to win share from these legacy incumbents ... and Livewire's James Marlay Zoe Middleton: One stock that you could hold in almost any environment would be ...

Shares of Haleon plc (NYSE:HLN – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the ...

Haleon plc (LSE/NYSE:HLN), a global consumer health leader with a market capitalization of $44 billion, disclosed today that two of its executives have acquired shares as part of the company's ...

Kenvue's improvements in marketing and management could drive future growth. Read why there is potential for a turnaround for ...

Barclays analyst Iain Simpson maintained a Buy rating on Haleon PLC (HLN – Research Report) today and set a price target of £4.15. The company’s shares closed yesterday at p375.70.

Haleon PLC HLN shares rallied 2.06% to £3.87 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.77% to 8,767.80. Haleon ...

Once complete, Pfizer's stake in Haleon will fall from 15.0% to around 7.3%. Pfizer's move comes after Haleon's spin-off as an independent consumer healthcare company, part of plans to reshape its ...

In an interview with Gulf Business, Charles Leslie, global business lead for the Pain Portfolio & Systemics at Haleon ... how we view health and wellness. One of the most noticeable trends ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...